ClinicalTrials.gg
CompletedNCT03492112TEMPOUpdated Jan 17, 2023

A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams

An interventional study of HCV RNA Point of Care and Sofosbuvir/velpatasvir in Hepatitis C, sponsored by Kirby Institute. Completed at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-17.

Sponsored by Kirby Institute · Not applicable, Interventional, and Screening

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
101
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 94 studies testing sofosbuvir in Hepatitis C — 1 open to participants now, 3 under way, none of them phase 3. Sofosbuvir · Hepatitis C.

Enrollment
38th of 94
101 · median 75
Started
2019
with 7 others
No phase
7 of 94
1 open now
Registered
72nd of 94
by date
Lead sponsor
3 of 94
Kirby Institute

Among the 94 studies testing sofosbuvir in Hepatitis C, this one is the 38th largest by enrollment, is one of 8 that started in 2019, is one of 7 with no phase, and was the 72nd registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

1 of the 94 studies testing sofosbuvir in Hepatitis C is open now. Recruiting first, the newest first:

About sofosbuvir

Sofosbuvir: first FDA approval 2013 (SOVALDI), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing sofosbuvir in Hepatitis C, or all of them as a file.
02

Study summary

TEMPO is an interventional cohort study recruiting injecting drug users attending needle and syringe programs (NSP) in Australia. Three hundred participants will be invited to on-site HCV testing with NSP integrated care for HCV treatment.

Participants will be screened for HCV using point-of-care testing and HCV positive participants will be offered treatment with Sofosbuvir/Velpatasvir. Of those who initiate treatment, participants will receive weekly peer-based support on-treatment and return at End of Treatment (ETR) and 12 weeks following end of treatment (SVR12) for clinical follow-up.

03

Conditions studied

  • Hepatitis C

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all the following inclusion criteria to be eligible to participate in this study:

  1. Participants have voluntarily signed the form;
  2. 18 years of age or older;
  3. Current injecting drug use (previous month);
  4. positive participants commencing treatment must be eligible to initiate therapy with Sofosbuvir/Velpatasvir; and
  5. In the opinion of the Investigator, the participant is suitable for NSP-based HCV treatment delivery.

Exclusion criteria

Exclusion criteria

  1. For positive participants commencing treatment:
  1. Any condition or history known to contraindicate the use of Sofosbuvir/Velpatasvir or would not be suitable for management within a NSP-based treatment setting;
  2. Any medication in the Sofosbuvir/Velpatasvir product information;
  3. Has previous HCV DAA treatment experience
  4. Has a fibroscan score > 12.5 Kpa
  5. co-infection
  6. co-infection
  7. Is female and is pregnant or breastfeeding
  8. Is unable or unwilling to provide or abide by the requirements of the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    People attending needle syringe programs in Australia

    Participants will be screened for Hepatitis C using the Finger-stick whole blood HCV RNA Point of Care GeneXpert. Participants with hepatitis C will be offered treatment with a pan-genotypic DAA HCV therapy- either 12 weeks of sofosbuvir/velpatasvir or 8 weeks of glecaprevir/pibrentasvir.

    Device: HCV RNA Point of Care · Drug: Sofosbuvir/velpatasvir · Drug: Glecaprevir/pibrentasvir

Interventions

  • DeviceHCV RNA Point of Care

    Participants attending needle syringe programmes in Australia will be screened for hepatitis C using the finger-stick whole blood GeneXpert HCV RNA cartridge.

    Also known as: GeneXpert System

  • DrugSofosbuvir/velpatasvir

    Drug pages: SofosbuvirStudies of SofosbuvirSofosbuvir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · VelpatasvirStudies of VelpatasvirVelpatasvir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.

    Also known as: Epclusa

  • DrugGlecaprevir/pibrentasvir

    Drug page: Glecaprevir and pibrentasvirStudies of Glecaprevir and pibrentasvirGlecaprevir and pibrentasvir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.

    Also known as: Maviret

06

What researchers measure

Primary outcomes

  1. Uptake of HCV DAA therapy among current PWID

    Treatment uptake (i.e. proportion of participants initiating DAA therapy)

    Time frame: 4 Weeks

07

Study locations

1 site
  • NUAA NSP
    Sydney, New South Wales 2010, Australia
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Nov 2021, 26 months.

Of 150 non-industry interventional studies with no phase under Hepatitis C, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's 26 months is close to that.

Counting every sponsor, half of 153 studies reached it within 25 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2018
First posted
Apr 10, 2018
StartActual
Sep 10, 2019
Primary completionActual
Nov 30, 2021
CompletionActual
Nov 30, 2021
Last update
Jan 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03492112
Lead sponsor
Kirby Institute
Responsible party
Sponsor
First posted
Apr 10, 2018
Start date
Sep 10, 2019
Primary completion
Nov 30, 2021
Completion
Nov 30, 2021
Last update
Jan 17, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sofosbuvir · Velpatasvir · Glecaprevir and pibrentasvir

Start the discussion